bio-harlan

John Harlan, M.D.

John Harlan, M.D., currently serves as President of Cardio-Thoracic Surgeons P.C. He earned his medical degree from the University of South Florida after receiving his bachelor’s degree from the University of Notre Dame. Dr. Harlan began his surgical training at the University of Alabama Hospital, studying General Surgery and completed his Thoracic and Cardiovascular Surgery training at the University of Iowa Hospitals and Clinics. He joined the Cardio-Thoracic Surgeons’ team in 1985. His Board Certifications include The American Board of Surgery 1983 and The American Board of Thoracic Surgery 1986.

Undergraduate Education:
09/1971 – 05/1974: University of Notre Dame

Medical School:
06/1974 – 06/1977: University of South Florida

Residencies:
07/1977 – 06/1982: University of Alabama Hospital, General Surgery
07/1982 – 06/1985: University of Iowa Hospital, Thoracic and Cardiovascular Surgery

Professional Experience:
07/1985 – Present: Cardio-Thoracic Surgeons, P. C.

Licensure:
07/17/1978: Board of Medical Examiners
03/22/1983: American Board of Surgery
05/24/1986: American Board of Thoracic Surgery

Research Experience:

2004
Alexion Pharma. And P&G Pharma. PRIMO-CABG II Trial Primary Investigator “A MUlticenter, Randomized, Double-Blind,
Parallel-group, Placebo-Controlled Study of 2 mglkg Bolus Plus 24-hour 0.05 mglkgfhr Infusion of Pexelizumab in Patients
Undergoing Coronary Artery Bypass Grafting withCardiopulmonary Bypass” Phase III

Medicure International, Inc.. MEND-CABG Trial Primary Investigator “A Randomized, Double-blind, Placebocontrolled,
Dose-ranging, Muti-centered Study To Evaluate The Cardiovascular and Cerebrovascular Effects of MC-1 in Patients
Undergoing High-risk CABG Surgery.” Phase II.

The Medicines Company. Eclipse 1 Trial Primary Investigator “Evaluation of Clevelox In the ferioperative Treatment of Hypertension Assessing §afety ];vents (with Nitroglycerin as Active Comparator” Phase III.

NIH – DUMC. Peri-operative Neuroprotection Trial

2003
BioMarin Pharmaceutical Inc. Protocol Number NTL06 Primary Investigator “A Phase III Comparison of Neutralase to Protamine in Patients Undergoing Primary CABG Procedures”

Corgentec Inc. Protocol Number CGT003.Q4: Primary Investigator “A Phase Ill, MultiCenter, Randomized, DOUble-Blind, Placebo
Controlled Trial of the Ex Vivo Treatment with CGT003 of Coronary Vein Grafts in Patients Undergoing CABG Procedures”

Pfizer Inc. Protocol Number A3181007: Primary Investigator “A DOUble-Blind, Placebo Controlled, Parallel Group StUdy of the
Effects of Zoniporide on Perioperative Cardiac Events in Subjects Undergoing Noncardiac Vascular Surgery”

2002
Pfizer Inc. Protocol Number A3181 006: SUb-Investigator “A Phase II, MultiCenter, Placebo Controlled. Randomized, Stratified,
Double-Blind, Dosing Regimen Optimization and Dose-Escalation Study to Evaluate the Safety, Toleration, and Clinical Pharmacology of Zoniporide Administered for up to 7 Days to SUbjects Undergoing CABG Surgery”

Research Certification:
OHRP Investigator 101, January 2005

Professional Societies:
The Medical Association of the State of Alabama
Jefferson CountyMedical Society
American Medical Association
John W. Kirklin Society
Fellow American College of Cardiology
FellowAmerican College of Surgeons
The Society of Thoracic Surgeons